Vasopressin (also known as antidiuretic hormone) is a nonapeptide produced in the paraventricular and supraoptic nuclei of the hypothalamaus and released from the posterior pituitary. It has two distinct roles that underlie its two names. In health, its main effect is to act in the control of osmolarity. Stimulation of vasopressin receptors (V2) in the distal convoluted tubule of the kidney results in water reabsorption and a fall in osmolarity. It has very little effect on blood pressure in health. In shock states, vasopressin binds to receptors in vascular smooth muscle that leads to vasoconstriction and maintenance of blood pressure. Interestingly, in shock states vasopressin has very little effect on osmolarity.
The mechanisms by which vasopressin cause vasoconstriction are complicated and beyond the scope of this review. An excellent review examining its mechanism of action is recommended. 1 In summary, in shock states vasopressin binds to G-protein-coupled V1 receptors on vascular smooth muscle that leads to increased intracellular calcium levels and vasoconstriction. Heterogeneity of the distribution of the V1 receptors may be important. For instance, there is a greater distribution of V1 receptors on renal efferent compared to renal afferent arterioles. This contrasts to the α-adrenoreceptor which is present on renal afferent and efferent arterioles so that noradrenaline vasoconstricts both renal afferent and efferent arterioles. Therefore, in comparison vasopressin may increase renal perfusion and glomerular filtration rate more than noradrenaline.
Vasopressin may also produce vasodilatation in some vascular beds. In part this may be due to the fact that vasopressin binds to the oxytocin receptor. Stimulation of these receptors, which are found in endothelial cells of the pulmonary, coronary and cerebral circulation, can result in nitric oxide-mediated vasodilatation. It is also possible that stimulation of V2 receptors in some vascular beds may lead to vasodilatation.
Vasopressin levels in septic shock
In health, vasopressin levels are generally less than ∼4 pmol/L; however, in shock states, large increases are seen. For instance, in cardiogenic shock vasopressin levels of more than 20 pmol/L have been reported. 2 In contrast, a relative vasopressin deficiency was seen in septic shock where levels remained low (∼2.8 pmol/L) despite similar degrees of hypotension. Subsequent studies have suggested that there may be an initial rise of circulating vasopressin in septic shock but that levels fall significantly within hours such that most septic shock patients develop a relative vasopressin deficiency. 3 This is probably due to a combination of depletion of vasopressin stores and inhibition of synthesis and release within the hypothalamus and posterior pituitary. 4 As well as this relative vasopressin deficiency in septic shock, there appears to be a simultaneous hypersensitivity to exogenous vasopressin, resulting in a marked reduction in catecholamine requirements. The mechanisms behind this hypersensitivity may include a change in vasopressin receptor expression and activity, inhibition of inducible nitric oxide synthase, closing of open potassium channels and potentiation of other vasopressor agents. 1 
Vasopressin in clinical studies of adult septic shock Efficacy
Most of the randomised controlled trials of vasopressin in septic shock have been small studies examining physiological endpoints. These studies have all shown that vasopressin increases blood pressure and reduces catecholamine infusion rates in patients who have septic shock. In a phase II study, Patel and colleagues compared blinded infusions of vasopressin and noradrenaline in 24 patients who had septic shock already receiving open-label noradrenaline. 5 During the four-hour study drug infusion period, in the vasopressin group (0.01-0.08 U/min) the noradrenaline requirements reduced significantly from 25 µg/min to 5 µg/min while the target blood pressure was maintained. Furthermore the urine output doubled and creatinine clearance increased. There was no change in any of these parameters in the noradrenaline group.
Similar beneficial effects of vasopressin on the kidney were seen in a study by Lauzier and colleagues who compared vasopressin to noradrenaline in a small trial of early hyperdynamic shock. 6 Patients were randomised to receive open-label infusions of either high dose vasopressin
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Keywords: vasopressin; septic shock; noradrenaline; corticosteroids; acute kidney injury (0.04-0.20 U/min) or noradrenaline (0.1-2.8 µg/kg/min). The main outcomes measured were haemodynamic variables and organ function over the 48-hour study drug infusion period. In the vasopressin group, there was reduced organ dysfunction at 48 hours (as exhibited by a lower modified SOFA score) and this difference was mainly due to the effect on renal function, where creatinine clearance improved significantly in the vasopressin group but there was no change in the noradrenaline group.
To date, the VASST study (Vasopressin in Septic Shock Trial) is the only trial of vasopressin large enough to meaningfully examine survival as an outcome. 7 This was a multi-centre double-blind randomised controlled trial that compared vasopressin (0.01-0.03 U/min) to noradrenaline (5-15 µg/min) in adult patients who had established septic shock (at least 5 µg/min of noradrenaline for at least six hours). In total, 779 patients were recruited from 27 centres in Canada, Australia and the USA. As expected, vasopressin treatment led to a marked decrease in catecholamine requirements while still maintaining the target blood pressure. However, there was no statistically significant difference in mortality between the treatment groups when all patients randomised and infused with the study drug were analysed (28-day mortality 35.4% in the vasopressin group and 39.3% in the noradrenaline group, p=0.26; 90-day mortality 43.9% in the vasopressin group and 49.6% in the noradrenaline group, p=0.11).
Interestingly, in the pre-defined stratum of less severe shock (defined as <15 µg/min of noradrenaline prior to randomisation) there was a statistically significantly lower mortality in the vasopressin group compared to the noradrenaline group (26.5% vs 35.7% respectively, p=0.05). In the more severe shock patients there was no difference in mortality between treatment groups. The explanation for this subgroup finding is unclear and possible explanations include the following hypotheses: 1. Vasopressin needs to be given earlier in the disease process while the pathology is more reversible Although there was no difference in time to infusion of study drug after meeting the trial' s inclusion criteria (12.3 hours vs 11.2 hours in less severe and more severe shock subgroups respectively) it is difficult to know when the sepsis episode actually started. In a post-hoc analysis there was a trend to improved survival in vasopressin-treated patients who received the study drug in the first 12 hours of the 24-hour recruitment window (vasopressin mortality 33.2% vs noradrenaline mortality 40.5%, p=0.12). In contrast, there was no difference in outcome if the study drug was started in the second 12 hours of the recruitment window (vasopressin mortality 37.7% vs noradrenaline mortality 37.5%, p=0.97).
Supporting this hypothesis is further recent data from the VASST study about renal function. 8 Using the RIFLE criteria to define the degree of kidney injury at randomisation, in "Risk" patients (n=106), vasopressin as compared to noradrenaline was associated with a lower rate of progression to renal ''Failure'' or ''Loss'' (20.8% vs 39.6%, respectively, p=0.03), and a lower rate of use of renal replacement therapy (17.0% vs 37.7%, p=0.02). Mortality rates in the ''Risk'' category patients treated with vasopressin compared to noradrenaline were 30.8% vs 54.7% respectively, p=0.01. There was no difference in any outcomes in patients who had more established renal dysfunction at randomisation.
Vasopressin may have led to earlier discontinuation of noradrenaline
Although vasopressin infusion led to a decrease in noradrenaline requirements in all patient groups (approximately 10 µg/min) this led to more patients in the less severe shock subgroup stopping all noradrenaline (by definition they were receiving 5-14 µg/min of noradrenaline at inclusion). Patients in the more severe shock subgroup (≥15 µg/min of noradrenaline at inclusion) would have had reduced noradrenaline requirements after starting vasopressin infusion but they were still receiving noradrenaline. If one of the beneficial effects of vasopressin is its catecholamine-sparing effect, then this is likely to be most evident in those in whom all or most catecholamine vasopressors can be discontinued early.
More vasopressin was required in the more severe shock subgroup
The maximum dose of vasopressin used in the VASST study was 0.03 U/min. This low-dose rate was selected due to the fact that there had been reports of adverse events (including sudden cardiac arrest) in patients receiving higher doses, generally >0.05 U/min. 9 However, most safety reports have come from retrospective uncontrolled studies. It is therefore difficult to assign adverse events due to the therapy or due to the underlying disease process.
It is possible that the reason no benefit from vasopressin was seen in the more severe shock subgroup in VASST was because they did not receive enough vasopressin. A recent randomised controlled trial compared two different doses of vasopressin and found that 0.067 U/min of vasopressin was more effective at restoring cardiovascular function in advanced vasodilatory shock than 0.033 U/min, without any adverse effects. 10 
Chance
Although the subgroup analysis was defined prospectively and the mortality reduction in patients treated with vasopressin in the less severe shock subgroup was statistically significant, this could still be a chance finding. The a priori hypothesis was that the greatest benefit was expected in the more severe shock subgroup, reflecting clinical practice at the time when vasopressin was used as a second line agent in refractory shock. Also, the interaction statistic comparing the treatment effect in both subgroups was not significant (p=0.1) and so we cannot conclude that the two subgroups are truly responding differently. Therefore further evidence is required before these subgroup results can be confidently incorporated into clinical practice.
Interaction with steroids
Recently it has been suggested that there may be an interaction between vasopressin and corticosteroids to decrease mortality rates in septic shock. 11, 12 Vasopressin and corticosteroids are both commonly used in septic shock and they both increase responsiveness to endogenous and infused catecholamines. However, little is known about how they interact. The VASST study 11 reported that a statistically significant interaction was found between vasopressin/noradrenaline treatment and corticosteroid treatment (interaction statistic p=0.008). The combination of vasopressin and steroids led to a significantly lower mortality compared to noradrenaline plus steroids (35.9% vs 44.7% respectively, p=0.03) and less organ dysfunction demonstrated by more days alive and free from shock, mechanical ventilation and renal failure. In contrast, patients who were treated with vasopressin and had no corticosteroids had a trend towards increased mortality (33.7% vs 21.3%, p=0.06). Interestingly, patients who received steroids as well as vasopressin had higher levels of circulating vasopressin compared to patients treated with vasopressin alone. This same effect of steroids on levels of vasopressin was seen in another recent vasopressin trial. 10 At both rates of vasopressin infusion, higher levels of vasopressin were measured in the patients treated with steroids compared to the patients treated without steroids.
The mechanism behind these findings remains uncertain at present. There are complex interactions between the hypothalamic-pituitary-adrenal axis and the hypothalamicpituitary-vasopressin axis. Vasopressin binds to V3 receptors located in the anterior pituitary and may increase adrenocorticotrophin hormone (ACTH) production and secretion. 13 Similarly, corticosteroids may increase vasopressin messenger RNA 14 but other studies have found that corticosteroids do not change vasopressin levels 15 and others have suggested that corticosteroids may actually suppress gene expression. 16 There is animal data to suggest that corticosteroids may increase the efficacy of vasopressin. In an endotoxaemia model, the vasopressor effect of vasopressin decreased over time but was then restored by administration of corticosteroids. 17 This data is further supported by another recent retrospective study that reported that the combination of vasopressin and corticosteroids to treat septic shock resulted in significantly more patients being alive and free from vasopressors at day 7 compared to vasopressin use alone. 18 
Safety
The most frequently reported adverse event associated with vasopressin use is a fall in cardiac output, 2, 6, [19] [20] [21] although an increase in cardiac output has also been reported. 22 In general, the decrease in cardiac output has been related to a fall in heart rate, as stroke volume has usually been unchanged. 6, 19, 21 Other cardiac concerns have included myocardial ischaemia. There was one case of myocardial ischaemia in a patient without known ischaemic cardiac disease induced by high dose vasopressin that resolved when vasopressin was stopped. 6 As mentioned above a retrospective case series reported that higher doses of vasopressin infusion (>0.05 U/min) were associated with an increased rate of cardiac arrest. 9 However, a recently completed prospective study found no adverse effects of vasopressin infusion at 0.067 U/min. 10 Vasopressin is routinely used for its splanchnic vasoconstrictor effects in patients with bleeding oesophageal varices and therefore there has been concern that vasopressin could cause mesenteric ischaemia in septic shock. Vasopressin was reported to increase the gastric to arterial CO 2 partial pressure gap, compatible with gastric hypoperfusion, in a dosedependent fashion in one small case series of patients who had septic shock. 23 In contrast, there was an improvement in gastrointestinal perfusion as assessed by gastric tonometry in a randomised controlled trial 22 and no effect on gastric-arterial PCO 2 gradient in another. 5 Adverse effects on liver function and platelet count have also been reported. [20] [21] [22] Vasopressin receptors are expressed on platelets 24 and vasopressin has been shown to cause platelet aggregation. 25 It has been suggested that this may contribute to ischaemic skin lesions in vasopressin-treated patients during septic shock. 22 Interestingly in this latter report it was increasing dose of noradrenaline, but not vasopressin, that was associated with ischaemic skin lesions.
In the VASST study there were no safety concerns. 7 The overall serious adverse event rate was very similar in the vasopressin and noradrenaline groups (10.3% and 10.5% respectively) and there was no difference in any of the specific categories of serious adverse events. In particular, there was no significant difference in the rates of myocardial, mesenteric or digital ischaemia, cardiac arrest, life-threatening arrhythmias, hyponatraemia, or cerebrovascular accident. Further post-hoc analyses of the VASST data found no difference in troponin levels or ischaemic ECG changes between patients treated with vasopressin or noradrenaline. 26, 27 
Current treatment guidelines
It is clear that vasopressin is an effective vasoconstrictor and spares catecholamine use. It would also appear that low-dose infusion (up to at least 0.03 U/min, and maybe as high as 0.067 U/min) is safe in septic shock.
It is more difficult to know how to use vasopressin most effectively. It would appear from the VASST study that using vasopressin as "rescue" therapy in the most severe cases of refractory shock is unlikely to produce significant outcome benefit. Beneficial effects, particularly on renal function, would appear to be most likely if vasopressin is used earlier in less severely ill patients.
Future research
The VANISH trial (VAsopressin vs Noradrenaline as Initial therapy in Septic sHock), selected in the 2008 ICS research priority setting exercise, aims to answer some of these uncertainties. 28 Since the original proposal, there have been changes to the design to make it a factorial 2x2 study with two treatment randomisations, 1 -vasopressin vs noradrenaline as the initial vasopressor and then 2 -hydrocortisone vs placebo as second line treatment, thus giving four treatment arms.
Currently the feasibility study (VACS-VAsopressin and Corticosteroids in Septic shock, http://www.controlledtrials.com/ISRCTN66727957/VACS) is recruiting and aims to test for a biological interaction between vasopressin and hyrdrocortisone, as well as inform the design of the subsequent VANISH trial. Hopefully these two trials, which are supported by the Intensive Care Foundation and the UK intensive care community, will provide valuable evidence on which to guide future vasopressor use in septic shock.
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